TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernels quantitative neuroimaging technology, Flow, to measure ketamines psychedelic effects on cerebral cortex hemodynamics.
The commencement of the Kernel feasibility study marks a truly exciting moment, not only for Cybin and Kernel, but also for the entire field of psychedelic drug development. To this point, studies have had to rely on subjective patient reporting. By deploying the innovative Flow technology, this is the first time any company has had the ability to collect and quantify longitudinal brain activity before, during and after a psychedelic experience. We are specifically encouraged by this scientific advancement as it has the potential for Cybin to collect real-time quantitative data for our promising psychedelic-based therapies. These data will support the Companys leading research position as we move our important treatment options through regulatory discussions and late-stage clinical development, said Doug Drysdale, Chief Executive Officer of Cybin.
Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain. Our collaboration with Cybin has the potential to significantly enhance the research evaluating the potential positive effects of psychedelic therapies on the brain to improve mental wellness, said Bryan Johnson, Founder and Chief Executive Officer of Kernel.
About the Feasibility Study:
The main objective of the Company-sponsored feasibility study is to evaluate a participants experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine. Participants will receive either a low dose of ketamine or placebo while wearing the Flow headset, which is equipped with hi-tech sensors to record brain activity and will report their experience using structured questionnaires and validated assessments during study visits and at follow-up. The four-week study will also evaluate brain activity before and after administrating the study agents - low-dose ketamine or placebo.
The feasibility study received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) authorization in October 2021 and Institutional Review Board (IRB) approval in January 2022.
As part of Cybins sponsorship of the feasibility study, the Company will retain an exclusive interest in any innovations that are discovered or developed through its independent analysis of the study findings.
About Kernel Flow
Kernel Flow is a wearable headset that measures brain activity by recording local changes in blood oxygenation. It is adjustable, can accommodate nearly anyone and is safe. Kernel Flow is groundbreaking neurotechnology because it reduces loud, expensive, and room-sized equipment to a head-worn apparatus while providing neural activity data of the highest possible optical quality. This combination has never existed in such a commercial and scalable device, all factors for why brain interfaces and neuroimaging technology has largely remained in academic labs or hospital basements and why mental health diagnosis and treatment have behavioral, instead of biomarker, endpoints. The entire system is the size and look of a bicycle helmet and could, in the future, be more broadly used for neuroscientific or physiological studies of brain activity during psychedelic use.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Cautionary Notes and Forward-Looking Statements
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybins future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words believe, expect, aim, intend, plan, continue, will, may, would, anticipate, estimate, forecast, predict, project, seek, should or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Companys proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens, including the anticipated results of using Kernel Flow technology, to potentially treat psychiatric disorders.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Companys operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company's management's discussion and analysis for the period ended December 31, 2021 and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on http://www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.
Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Read more from the original source:
- Georgia Tech to Offer Ph.D. in Neuroscience and Neurotechnology, New Minor | News Center - Georgia Tech News Center - May 3rd, 2024 [May 3rd, 2024]
- China developed its very own Neuralink Neucyber brain interface comes from a neurotechnology firm - Tom's Hardware - May 3rd, 2024 [May 3rd, 2024]
- Tether Acquires Majority Stake in Blackrock Neurotech - PYMNTS.com - May 3rd, 2024 [May 3rd, 2024]
- China Shows Off Monkey With Brain Chip Allowing It to Control Robotic Arm - Futurism - May 3rd, 2024 [May 3rd, 2024]
- World must act on neurotech revolution, say experts - The Star Online - May 3rd, 2024 [May 3rd, 2024]
- Opinion | The Fight for Your Kids' Brains Has Already Begun - The New York Times - September 9th, 2023 [September 9th, 2023]
- DEFENDING THE BRAIN | Duke Mag - Duke University - September 9th, 2023 [September 9th, 2023]
- The Innovations and Success of Elon Musk - OPP.Today - September 9th, 2023 [September 9th, 2023]
- Top Companies Using AI to Transform the Healthcare Industry ... - Cryptopolitan - September 9th, 2023 [September 9th, 2023]
- UN Warns Unregulated Neurotechnology Threatens 'Freedom of Thought' - Yahoo News - July 23rd, 2023 [July 23rd, 2023]
- I felt like there was someone in my head, and it wasn't me. - UNESCO - July 23rd, 2023 [July 23rd, 2023]
- Unraveling Connections Between the Brain and Gut - The Good Men Project - July 23rd, 2023 [July 23rd, 2023]
- Neurotechnology: what it is, applications - Iberdrola - February 10th, 2023 [February 10th, 2023]
- Forget Media Manipulation And Misinformation via TikTok And Twitter, Neurotechnology Heralds The New Battle For Our Brains - Forbes - February 10th, 2023 [February 10th, 2023]
- The Jacob Laboratory Translational Neurotechnology - January 2nd, 2023 [January 2nd, 2023]
- Massachusetts Institute Of Technology Experts Come Together In A Play Inspired By Advances In Neurotechnology - India Education Diary - January 2nd, 2023 [January 2nd, 2023]
- Neurotechnologies: The Next Technology Frontier | IEEE Brain - December 18th, 2022 [December 18th, 2022]
- Twelve Neurotechnology Startups to Present at 2022 Neurotech Leaders ... - November 19th, 2022 [November 19th, 2022]
- Research Experience for Undergraduates | Center for Neurotechnology - November 8th, 2022 [November 8th, 2022]
- Axoft Launches Brain Implant Technology to Treat Long-Term Neurological Disorders and is Granted FDA Breakthrough Device Designation - Business Wire - October 19th, 2022 [October 19th, 2022]
- Researcher combines AI and microelectronics to create neural implants that fight brain disorders - University of Toronto - October 19th, 2022 [October 19th, 2022]
- Global Contactless Biometrics Technology Market Size And Forecast | Aware Inc., Fingerprint Cards AB, Fujitsu Limited, Gemalto N.V., HID Global,... - October 19th, 2022 [October 19th, 2022]
- Facial Recognition Market Size and Share 2022 | Global Industry Analysis, Feasibility Study and Development Scope by 2032 | NEC Corporation (NEC)... - October 17th, 2022 [October 17th, 2022]
- Pitt scientists awarded $8 million for neurotechnology to restore arm and hand movements after strokes - University of Pittsburgh - October 15th, 2022 [October 15th, 2022]
- UN: Highlights from the 51st Session of the Human Rights Council - ARTICLE 19 - Article 19 - October 15th, 2022 [October 15th, 2022]
- PD Neurotechnology, a MedTech start-up for patients suffering from ... - October 8th, 2022 [October 8th, 2022]
- Brain ScienceConsciousness as the Property of Thought | Neurotech - VGR.com - October 6th, 2022 [October 6th, 2022]
- Facial Recognition Technology Market to witness a substantial growth owing to rising adoption of technology till 2032 | NEC Corporation, Aware,... - October 6th, 2022 [October 6th, 2022]
- ARC Future Fellowships awarded to Turner Institute researchers - Monash University - September 17th, 2022 [September 17th, 2022]
- Critics Picks: Cate Blanchett, Steven Spielberg Films Among the 15 Best of the Fall Festivals - Hollywood Reporter - September 17th, 2022 [September 17th, 2022]
- Stryker Launches Pulse Intelligent Delivery Platform at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting - Business Wire - September 17th, 2022 [September 17th, 2022]
- If separating conjoined twins results in death, which one should die? - Big Think - September 17th, 2022 [September 17th, 2022]
- Theater of Thought Review: Werner Herzog Crafts a Bracing Exploration of Neurotechnology and Consciousness - Hollywood Reporter - September 7th, 2022 [September 7th, 2022]
- Elon Musk seeks to expand his empire in the world of neurotechnology - Gearrice - September 7th, 2022 [September 7th, 2022]
- VoxNeuro Announces Collaboration with Boston University and Launch of Clinical Studies Focusing on Concussion and Alzheimers Disease - Yahoo Finance - September 7th, 2022 [September 7th, 2022]
- Tri-anim Health Services announces exclusive relationship to distribute BrainScope's breakthrough technology for mild head injury including... - September 7th, 2022 [September 7th, 2022]
- Interaxon Inc. (Muse) Highlights Myndlifts Preliminary Study and the Benefit of Partnerships for Digital Therapeutics Research - BioSpace - September 7th, 2022 [September 7th, 2022]
- Elon Musk and Neuralink executive Shivon Zilis reportedly conceived twins via IVF - The Independent - August 29th, 2022 [August 29th, 2022]
- Biometric Wearable Market Research Insights with Trends, Competitive Analysis, Opportunities, Forecast 2022 to 2030 Muleskinner - Muleskinner - August 29th, 2022 [August 29th, 2022]
- Neurotechnology - the future of the legal profession? - Lexology - August 25th, 2022 [August 25th, 2022]
- Future criminals could be monitored by chips in their brains, experts claim... - The US Sun - August 25th, 2022 [August 25th, 2022]
- Stryker to participate in the 2022 Wells Fargo Securities Healthcare Conference - GuruFocus.com - August 25th, 2022 [August 25th, 2022]
- Investing in Brain Research and Neuroengineering - University of Houston - August 2nd, 2022 [August 2nd, 2022]
- Hamilton-based Zentrela working to understand the cannabis experience - Hamilton Spectator - August 2nd, 2022 [August 2nd, 2022]
- IntualityAI may be Able to Provide Psychotherapy for Robots in Future - AZoRobotics - August 2nd, 2022 [August 2nd, 2022]
- Coconuts, Corporations: On Vauhini Vara's The Immortal King Rao - lareviewofbooks - August 2nd, 2022 [August 2nd, 2022]
- MindMaze Enters New Strategic Partnership with Alfa Romeo F1 Team ORLEN to Advance Technologies for Brain Health, Safety, and Performance - Yahoo... - July 13th, 2022 [July 13th, 2022]
- MindMaze Receives Recognition as one of Switzerland's Best Managed Companies - Business Wire - July 13th, 2022 [July 13th, 2022]
- OpenBCI and Varjo Partner to Bring Neurotechnology to Spatial Computing - July 11th, 2022 [July 11th, 2022]
- Three top technologies taking healthcare by storm - Kalkine Media - July 11th, 2022 [July 11th, 2022]
- It is time to leverage technology to correct the challenges people have with their minds: Antano Solar, CE.. - ETHealthWorld - July 11th, 2022 [July 11th, 2022]
- Elon Musk Secretly Fathered Twins With His Company's Executive: Report - KFI AM 640 - July 11th, 2022 [July 11th, 2022]
- Stryker to host conference call on July 26, 2022 - GuruFocus.com - July 11th, 2022 [July 11th, 2022]
- Neurotechnology Announces MOSIP Integration and Support in MegaMatcher SDK and ABIS - PR Newswire - June 15th, 2022 [June 15th, 2022]
- Musk's Twitter $44 Billion Bid Includes Financier Close to Russia - Report By Investing.com - Investing.com - June 15th, 2022 [June 15th, 2022]
- Stryker Strengthens Its R&D Capabilities with Advanced Global Technology Center - Press Trust of India - Press Trust of India - June 9th, 2022 [June 9th, 2022]
- Cuba is the only nation with a governmental science and technology program on the brain - Granma English - June 9th, 2022 [June 9th, 2022]
- 3 Disruptive Tech Stocks to Go All In on Now - InvestorPlace - June 9th, 2022 [June 9th, 2022]
- OpenBCI and Varjo Partner to Bring Neurotechnology to Spatial Computing - PR Newswire - June 5th, 2022 [June 5th, 2022]
- 3D Reconstruction Technology Market Size, Scope and Forecast | 3D Reconstruction, Eos Systems Inc., Everest Innovation Technology, Microsoft, NAVVIS,... - June 5th, 2022 [June 5th, 2022]
- Fingerprint Biometrics in the VAR Market to Eyewitness Massive Growth by 2031 The Greater Binghamton Business Journal - The Greater Binghamton... - June 5th, 2022 [June 5th, 2022]
- Horrors of Elon Musks Neuralink REVEALED including brain hacking technology and animal deaths... - The Scottish Sun - May 25th, 2022 [May 25th, 2022]
- Stryker Co. (NYSE:SYK) Receives Consensus Rating of Buy from Brokerages - Defense World - May 25th, 2022 [May 25th, 2022]
- Evon Medics, LLC Has Been Awarded $2.8 Million Grant for the Development and Evaluation of its Mobile Health Platform for Remote Management of... - May 11th, 2022 [May 11th, 2022]
- Mobile Biometrics Market Analysis by Size, Business Strategies, Share, Growth, Trends, Revenue, Competitive Landscape and Developments Forecast by... - May 11th, 2022 [May 11th, 2022]
- Dubai on the Brain: NeuroVigil's Philip Low Assembles ... - May 6th, 2022 [May 6th, 2022]
- Research Associate: Participatory Research and Communications Officer job with KINGS COLLEGE LONDON | 292429 - Times Higher Education - May 6th, 2022 [May 6th, 2022]
- Face Recognition Software Market 2022: Size, Industry Share, Approaches, and Forecast By 2028, (Idemia (FR), Aware (US), Leidos (US), BioID (DE)) ... - May 6th, 2022 [May 6th, 2022]
- Stocktake: Investors wary on Musk's Twitter deal - The Irish Times - May 6th, 2022 [May 6th, 2022]
- Hydrocolloid Dressing Market Competitive Landscape Analysis With Forecast by 2027 - BioSpace - May 6th, 2022 [May 6th, 2022]
- Futuristics Overview of Neural Control Market: Industry Insights and Forecast 2022-2028 by MIT, Hebrew university, Haier, Neurotechnology,,, and more... - May 3rd, 2022 [May 3rd, 2022]
- Brain Computer Interface (BCI) Market Poised to Garner a Valuation of USD 5.48 Billion by 2030, Growing at a 14.72% CAGR - Report by Market Research... - May 3rd, 2022 [May 3rd, 2022]
- Stryker's InSpace subacromial balloon spacer two-year, Level 1 randomized controlled clinical study published in the Journal of Bone and Joint Surgery... - May 3rd, 2022 [May 3rd, 2022]
- Stryker to participate in the Bank of America Securities 2022 Health Care Conference - Benzinga - Benzinga - May 3rd, 2022 [May 3rd, 2022]
- Earnings week 2: Supply chain shortages slowed ResMed, other medtechs from meeting demand - MedTech Dive - May 3rd, 2022 [May 3rd, 2022]
- Mind-reading technology Are we ready for it? - Freethink - April 25th, 2022 [April 25th, 2022]
- The brain implant that can translate your thoughts into text - SBS News - April 15th, 2022 [April 15th, 2022]
- Stryker says 88 jobs to be eliminated in May, part of previously announced layoff schedule - The Ledger - April 15th, 2022 [April 15th, 2022]
- Moon Rabbit Collaborates with Foresight Institute to Speed Up Life Extension Research - CryptoNewsZ - April 4th, 2022 [April 4th, 2022]
- Restoring touch through electrodes implanted in the human brain will require engineering around a sensory lag - The Conversation Indonesia - March 31st, 2022 [March 31st, 2022]